

FOR RELEASE:

Vybion Licenses ProCode™ Platform

Ithaca, NY: Vybion has exclusively licensed a drug development platform from Cornell University. The Platform, called ProCode, can be configured for monoclonal antibody selection, affinity maturation and library generation, for improving solubility and bioactivity of biopharmaceuticals, as well as identification and characterization of protein-protein interactions and discovery of protein drugs. ProCode offers several important advantages that strongly differentiate it from other technologies including dramatic reductions in drug development time, cost, and ease of use

Vybion has licensed patents developed by Drs. George Gorgiou and Matthew DeLisa together at the University of Texas at Austin and patents developed independently by Dr. DeLisa at Cornell University. These technologies are based on the Twin Arginine Transport System for which the inventors have an extensive peer reviewed publication portfolio

Vybion uses this technology for in house drug development, partner projects and the Company can sublicense these rights. “We believe this technology, coupled with our NIH supported research in collaboration with Dr. DeLisa, will continue to push the frontiers of this technology” said Dr. Lee Henderson, Vybion’s CEO

Lee A. Henderson, Ph.D.
President & CEO
lhenderson@vybion.com
607-266-0860 ext 223

John D. Noti, Ph.D.
Director, Research & Development
jnoti@vybion.com
607-266-0860 ext 224

Vybion, Inc.
33 Thornwood Dr.
Ithaca, NY 14850

About Vybion, Inc.

Vybion is an early stage developer of recombinant proteins for biopharmaceuticals and diagnostics. Vybion’s ProCode™ platform rapidly selects and affinity matures human monoclonal antibodies and optimizes solubility. The Company has developed over 100 proteins, has proprietary technologies in the areas of drug discovery, development and gene expression and is experienced in optimization of gene expression, fermentation, upstream and downstream process development and scale up for clinical manufacturing. Vybion technologies are a result of over 10 years of collaborative and internal research.